WO2007114475A1 - C-グリコシド誘導体とl-プロリンとの共結晶 - Google Patents
C-グリコシド誘導体とl-プロリンとの共結晶 Download PDFInfo
- Publication number
- WO2007114475A1 WO2007114475A1 PCT/JP2007/057597 JP2007057597W WO2007114475A1 WO 2007114475 A1 WO2007114475 A1 WO 2007114475A1 JP 2007057597 W JP2007057597 W JP 2007057597W WO 2007114475 A1 WO2007114475 A1 WO 2007114475A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- crystal
- proline
- present
- glucitol
- anhydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Definitions
- the present invention provides (1S) -1,5 anhydro 1- [3- (1-benzochen-2-ylmethyl) -4-fluorophenol] -D glucitol (hereinafter referred to as “C-glycoside derivative A”) It is simply referred to as “known compound A”) and L proline. More specifically, it contains a co-crystal of C-glycoside derivative A and L proline having a certain quality and excellent storage stability as a drug substance crystal used in the manufacture of pharmaceuticals, and contains this as an active ingredient. In particular, it relates to a pharmaceutical composition useful as a therapeutic agent for diabetes.
- Power Na + glucose cotransporter inhibitors include, for example, diabetes, such as insulin-dependent diabetes (type 1 diabetes), non-insulin-dependent diabetes (type 2 diabetes), treatment of insulin-resistant diseases and obesity, and It is reported that these compounds are useful for prevention (see Patent Document 1: Example 138).
- Patent Document 1 Pamphlet of International Publication No. 2004/080990
- the known compound A exists as a nonionic compound at a normal pH. Therefore, the above problem could not be avoided by forming a pharmaceutically acceptable salt.
- the present invention has been made to solve the above-mentioned problems, and is a co-crystal of a known compound A having a certain quality and excellent storage stability and suitable as a crystal of a drug substance used for a pharmaceutical product.
- the purpose is to provide.
- the present inventors diligently studied the formation of a co-crystal of the known compound A and an amino acid.
- co-crystal of the present invention the following co-crystal of C-glycoside derivative A and L proline (hereinafter sometimes referred to as “co-crystal of the present invention”), and effective
- a pharmaceutical composition useful as a therapeutic agent for diabetes is provided.
- a pharmaceutical composition comprising the co-crystal according to any one of [1] to [5] as an active ingredient.
- a therapeutically effective amount of the co-crystal according to any one of [1] to [5] above is administered to a patient
- a method for treating diabetes including
- a drug substance crystal for use in pharmaceuticals it contains a co-crystal of a known compound A and L proline having a certain quality and excellent storage stability, and contains this as an active ingredient.
- a pharmaceutical composition useful as a therapeutic agent for diabetes is provided.
- FIG. 2 is a powder X-ray diffraction pattern of (1S) -1,5 anhydro 1- [3- (1-benzochen-2-ylmethyl) 4-fluorophenyl] D-glucitol (known compound A).
- FIG. 3 is a differential scanning calorimeter analysis diagram (DSC analysis diagram) of L-proline.
- FIG. 4 is a powder X-ray diffraction pattern of L-proline.
- FIG. 8 is a powder X-ray diffraction pattern comparing the co-crystal of the present invention with that before storage.
- FIG. 9 is an adsorption and desorption isotherm of (1S) — 1,5 anhydro 1- [3- (1-benzochen-2-ylmethyl) 4 -fluorophenyl] D glucitol (known compound A).
- the co-crystal of the present invention unlike the crystals that form clathrate hydrates as described above, a single co-crystal having a certain quality can be obtained with good reproducibility and used for the manufacture of a medicine. It can be stably supplied as a crystal of the active drug substance and has excellent storage stability.
- the difference in crystal form between the known compound A forming the clathrate hydrate and the co-crystal of the present invention is particularly clear from the results of differential scanning calorimetry analysis (DSC analysis) and powder X-ray prayer.
- the co-crystal of the present invention has an endothermic peak at 201 to 213 ° C. by differential scanning calorimetry analysis (DSC analysis) and / or 2 ⁇ (°) 4.14 by powder X-ray diffraction. 8. 98, 12.4, 16.5, 17.5, 18.7, 20.5, and 21.5.
- the known compound A is characterized by the diffraction angle (2 0 (°)) and relative intensity in the powder X-ray diffraction spectrum shown in Table 1.
- the co-crystal of the present invention is characterized by the diffraction angle (2 ⁇ (°;)) and relative intensity in the powder X-ray diffraction spectrum shown in Table 2.
- Powder X-ray diffraction is based on the nature of the data, and crystal lattice spacing and the overall pattern are important in determining the identity of crystals. Relative strength depends somewhat on the crystal growth direction, particle size, and measurement conditions. Since it can change, it should not be understood strictly. [0031] [Table 1]
- the crystal forming the clathrate hydrate (known compound A) has a non-stoichiometric hydrate, which causes a shift in crystal plane spacing and a phenomenon that the diffraction angle shifts. It is done.
- Humidity control “Using MAC Science MXP18TAHF22J with multi-functional humidity temperature converter (VAISALA MHP235), tube: Cu, tube current: 350 mA, tube voltage: 50 kV, sampling width: 0. 020 °, scanning speed: 3 ° Measurement was performed under the conditions of wavelength: 1.54056 and measurement diffraction angle range (20): 5 to 40 °.
- the co-crystal of the present invention can be produced using the free form of C-glycoside derivative A described in Example 138 of Patent Document 1 and L-proline as shown in the following formula. That is, (IS) — 1, 5 Anhydro 1- [3— (1-Benzocene 1-ylmethyl) 4— Fluorophenol] D-glucitol (known compound A) and L-proline were heated and stirred in an appropriate solvent at a molar ratio of about 1: 1, and the reaction solution was gradually cooled while stirring and precipitated. Filter off the solid. After drying the solid obtained by washing with an appropriate solvent, recrystallization is performed using an appropriate solvent, and the precipitated crystals are collected by filtration.
- the solvent include alcohols such as methanol, ethanol, 2-propanol, and n-propanol, water, and a mixed solvent thereof.
- the temperature at the time of heating and stirring is usually about 40 to 150 ° C, preferably about 60 to 100 ° C.
- the time for heating and stirring is usually about 15 minutes to 2 hours, preferably about 20 minutes to 1 hour.
- the temperature at the time of cooling and stirring is usually about ⁇ 20 to 20 ° C., preferably about 0 to 10 ° C.
- the time for cooling and stirring is usually about 30 minutes to 3 hours, preferably about 1 to 2 hours. Drying is usually performed under reduced pressure heating conditions.
- the drying temperature is usually about 30 to 100 ° C, preferably about 40 to 60 ° C.
- the co-crystal of the present invention that can be obtained as described above is obtained by using C-glycoside derivative A and L-porin at a molar ratio of about 1: 1. For this reason, the co-crystal of the present invention is usually considered to be a co-crystal having a molar specific ratio of 1: 1 between C-glycoside derivative A and L-proline.
- the pharmaceutical yarn composition of the present invention contains the above-mentioned crystal of the present invention as an active ingredient.
- the pharmaceutical composition of the present invention is produced using the above-described crystal of the present invention.
- the pharmaceutical composition of the present invention may contain a pharmaceutically acceptable carrier as a component other than the above-described crystal of the present invention, and is particularly useful as a therapeutic agent for diabetes.
- a pharmaceutical composition containing the co-crystal of the present invention as an active ingredient is prepared using tablets, powders, fine granules, and granules using commonly used carriers and excipients for preparations, and other additives. It is prepared into capsules, pills, liquids, injections, suppositories, ointments, patches, etc. and administered orally or parenterally.
- the clinical dose (therapeutically effective amount) of the co-crystal of the present invention for humans is appropriately determined in consideration of the applied patient's symptoms, body weight, age, sex, etc. 0.1 to 500 mg, parenterally 0.01 to 100 mg, which should be administered once or in several divided doses. Since the dosage varies depending on various conditions, an amount smaller than the above dosage range may be sufficient.
- solid composition for oral administration of the cocrystal of the present invention tablets, powders, granules and the like are used.
- one or more active substances are present in at least one inert diluent such as lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, polypyrrole pyrrolidone. , Metasilicate mixed with magnesium aluminate.
- the composition may contain additives other than inert diluents, such as lubricants such as magnesium stearate, disintegrants such as calcium calcium glycolate, stabilizers such as ratatoses, glutamic acid or It may contain solubilizers or solubilizing agents such as aspartic acid.
- lubricants such as magnesium stearate
- disintegrants such as calcium calcium glycolate
- stabilizers such as ratatoses
- glutamic acid or It may contain solubilizers or solubilizing agents such as aspartic acid.
- tablets or pills may be coated with a sugar coating such as sucrose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose phthalate, or a film of a gastric or enteric substance.
- Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs and the like, commonly used inert diluents, Examples include purified water and ethyl alcohol.
- This composition may contain solubilizers, solubilizers, wetting agents, suspending agents, sweeteners, flavors, fragrances, preservatives in addition to the inert diluent. Good.
- Injections for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
- aqueous solution and suspension diluent include distilled water for injection and physiological saline.
- diluents for non-aqueous solutions and suspensions include Examples include vegetable oils such as propylene glycol, polyethylene glycol, olive oil; alcohols such as ethyl alcohol; polysorbate 80 (trade name).
- Such a composition further comprises an isotonic agent, preservative, wetting agent, emulsifier, dispersant, stabilizer.
- Additives such as (eg, ratatoses), solubilizers or solubilizers may be included. These are sterilized by, for example, filtration through a bacteria-retaining filter, blending with a bactericide or irradiation. These can also be used by preparing a sterile solid composition and dissolving it in sterile water or a sterile solvent for injection before use.
- Fig. 3 shows the differential scanning calorimeter analysis diagram (DSC analysis diagram) of L-proline
- Fig. 4 shows the powder X-ray diffraction diagram.
- D Glucitol and L-proline co-crystal have excellent storage stability, Na + glucose cotransporter inhibitory action and hypoglycemic action.
- a glucose cotransporter inhibitor for example, for treatment of insulin-resistant diseases and obesity, and prevention thereof, in addition to diabetes such as insulin-dependent diabetes (type 1 diabetes) and non-insulin-dependent diabetes (type 2 diabetes). Useful.
- Powder X-ray diffraction was measured continuously under the conditions of temperature: 25 ° C, measurement range: relative humidity of 2 to 88%.
- the known compound A was confirmed to have a diffraction angle shift accompanying a change in relative humidity (see FIG. 7).
- crystals that have obtained many crystallization conditions in free form are physically unstable crystals that reversibly form non-stoichiometric clathrate hydrates at room temperature and low humidity.
- the co-crystal of the present invention was strong even when allowed to stand for 7 days at room temperature (25 ° C), 63.5% RH to 84% RH, with no physical change observed. (See Figure 8). Furthermore, it was physically stable for at least two months even under conditions of 40 ° C / 75% RHH open, 60 ° CZ drift humidity, and 80 ° CZ drift humidity.
- the weight change was measured under the conditions of temperature: 25 ° C., measurement range: relative humidity 5 to 95%, measurement interval: relative humidity 5%.
- the known compound A exhibited a non-stoichiometric hygroscopicity with a low humidity force and a physical change. In particular, it showed a sudden weight increase from 25 to 35% relative humidity (see Figure 9).
- the moisture absorption curve varies slightly depending on the crystal size, it has been confirmed that it desorbs 3.2% of moisture at 25 ° C and relative humidity of 5 to 95%.
- the co-crystal of the present invention had a moisture retention of 0.7% or less over the entire range of 5 to 95% relative humidity, and did not exhibit hygroscopicity (see FIG. 10). It was also physically stable.
- single-stranded cDNA was reverse-transcribed from total RNA derived from human kidney (Clontech) using Superscript II (Gibco) and random hexamer.
- human SGLT2 (Wells RG et al., Am. J. Physiol, 1992, 263 (3) F459) was encoded by PCR using Pyrobe st DNA polymerase (manufactured by Takara).
- the DNA fragment to be amplified was amplified (a primer in which a Hind III site was introduced on the 5 ′ side and an EcoRI site on the 3 ′ side of the DNA fragment was used).
- Escherichia coli JM109 was grown in LB medium containing ampicillin (lOOmgZL).
- Proliferated Escherichia coli was purified by Hanahan's method (see Maniatis et al., Molecular Cloning).
- the DNA fragment encoding human SGLT2 obtained by purifying rasmid and digesting this plasmid with HindIII and EcoRI was used at the same site of expression vector pcDNA3.1 (Invitrogen) using T4 DNA ligase (Roche Diagnostics). I ligated and crawled.
- the ligated clone was introduced into a competent cell of E. coli strain JM109 in the same manner as described above, grown in LB medium containing ampicillin, and a human SGLT2 expression vector was obtained by the method of Hanahan.
- the human SGLT2 expression vector was introduced into CHO-K1 cells using Lipofectamine 2000 (G3 ⁇ 4co). After gene transfer, the cells were treated with penicillin (50 IUZmL, manufactured by Dainippon Pharmaceutical Co., Ltd.), streptomycin (50 ⁇ gZmL, manufactured by Dainippon Pharmaceutical Co., Ltd.), Geneticin (40 ⁇ g / mL 0 Gibco), and 10% Ushi fetal serum Incubated in Ham, s F12 medium (Nissui Pharmaceutical Co., Ltd.) in the presence of 37 ° C in the presence of 5% CO for 2 weeks to obtain Geneticin resistant clones. These claws
- Cells that stably express human SGLT2 were selected from the specific activity of glucose uptake in the presence of sodium relative to the steady level as an index (see the following sections for details of the method for measuring sugar uptake).
- Human SGLT2 stably expressing CHO cell culture medium was removed, and pretreatment buffer per well (140 mM choline chloride, 2 mM potassium chloride, lmM calcium chloride, 1 mM magnesium chloride, 2— [4— (2 hydroxyethyl) —1 [Piperazyl] ethanesulfonic acid 10 mM and tris (hydroxymethyl) aminomethane 5 mM buffer solution pH7.4) was added to 100 L and allowed to stand at 37 ° C. for 20 minutes.
- pretreatment buffer per well 140 mM choline chloride, 2 mM potassium chloride, lmM calcium chloride, 1 mM magnesium chloride, 2— [4— (2 hydroxyethyl) —1 [Piperazyl] ethanesulfonic acid 10 mM and tris (hydroxymethyl) aminomethane 5 mM buffer solution pH7.4
- Uptake buffer containing the co-crystal of the present invention salt sodium 140 mM, potassium salt 2 mM, calcium chloride lmM, magnesium chloride lmM, methyl-a-D-darcopyranoside 50 ⁇ , 2- [4- (2 hydroxyethyl) 1 piperazuryl] ethanesulfonic acid 10 mM, tris (hydroxymethyl) aminomethane 5 mM buffer pH 7. 11 ⁇ L methyl-a- D- (U— 14C) darcobilanoside ( Amersham Pharmacia Biotech Co., Ltd.) was added and mixed to obtain an uptake buffer, and a control uptake buffer containing no cocrystal of the present invention was prepared as a control group.
- a basic uptake buffer containing 140 mM salty choline was prepared in the same manner for the basic uptake measurement.
- the pretreatment buffer was removed, 25 ⁇ L of the uptake buffer was added per tool, and allowed to stand at 37 ° C for 2 hours.
- Remove the uptake buffer and wash buffer (choline chloride 140 mM, potassium chloride 2 mM, calcium chloride lmM, magnesium chloride lmM, methyl- ⁇ — D-darcobilanoside 10 mM, 2- [4— (2 hydroxyethyl) 1 —Pipelajur]
- a buffer solution containing 10 mM ethanesulfonic acid and 5 mM tris (hydroxymethyl) aminomethane, pH 7.4) was added in an amount of 200 L / ul and immediately removed.
- the IC value of the co-crystal was 5.8 nM.
- Non-fasted KK-A y mice (Japan Claire, male) were used as experimental animals.
- the co-crystal of the present invention was suspended in a 0.5% aqueous methylcellulose solution to a concentration of 1 mgZlOmL.
- the body weight of the mice was measured, and the suspension of the co-crystal of the present invention was forcibly orally administered at a dose of lOmLZkg, and only 0.5% aqueous methylcellulose solution was administered to the control group.
- the number of animals per group was 6. Blood was collected from the tail vein immediately before drug administration and at 1, 2, 4 and 8 hours after drug administration, and the blood glucose level was measured using Glucose CII Test Sakai (Wako Pure Chemical Industries).
- the strength of blood glucose lowering action was calculated from the blood glucose level over time from 0 to 8 hours in the co-crystal administration group of the present invention using the trapezoidal method to calculate the area under the blood glucose level hourly curve (AUC). Evaluation was based on the percentage of descent relative to descent. As a result, the co-crystal of the present invention showed a strong hypoglycemic effect.
- the co-crystal of the present invention showed a remarkable Na + glucose cotransporter activity inhibitory action and a strong hypoglycemic action. It is expected that it can be a therapeutic agent for diabetes having further efficacy.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008508716A JP5210154B2 (ja) | 2006-04-05 | 2007-04-04 | C−グリコシド誘導体とl−プロリンとの共結晶 |
KR1020087027002A KR101243039B1 (ko) | 2006-04-05 | 2007-04-04 | C-글리코시드 유도체와 l-프롤린과의 공결정 |
US12/296,056 US8097592B2 (en) | 2006-04-05 | 2007-04-04 | Cocrystal of C-glycoside derivative and L-proline |
BRPI0710581-9A BRPI0710581A2 (pt) | 2006-04-05 | 2007-04-04 | co-cristal de derivado de c-glicosìdeo e l-prolina |
AU2007232763A AU2007232763B2 (en) | 2006-04-05 | 2007-04-04 | Cocrystal of C-glycoside derivative and L-proline |
CA2649022A CA2649022C (en) | 2006-04-05 | 2007-04-04 | Cocrystal of c-glycoside derivative and l-proline |
MX2008012705A MX2008012705A (es) | 2006-04-05 | 2007-04-04 | Cocristal de derivado de c-glucosido y l-prolina. |
EP07741033A EP2009010A4 (en) | 2006-04-05 | 2007-04-04 | COCRISTAL OF THE DERIVATIVE OF C-GLYCOSIDE AND L-PROLINE |
CN2007800169018A CN101443328B (zh) | 2006-04-05 | 2007-04-04 | C-糖苷衍生物和l-脯氨酸的共结晶体 |
IL194512A IL194512A0 (en) | 2006-04-05 | 2008-10-02 | Cocrystal of c-glycoside derivative and l-proline |
ZA2008/09201A ZA200809201B (en) | 2006-04-05 | 2008-10-27 | Cocrystal of C-glycoside derivative and L-proline |
NO20084659A NO20084659L (no) | 2006-04-05 | 2008-11-04 | Ko-krystall av C-glucosidderivat og L-prolin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006-103711 | 2006-04-05 | ||
JP2006103711 | 2006-04-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007114475A1 true WO2007114475A1 (ja) | 2007-10-11 |
Family
ID=38563736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/057597 WO2007114475A1 (ja) | 2006-04-05 | 2007-04-04 | C-グリコシド誘導体とl-プロリンとの共結晶 |
Country Status (15)
Country | Link |
---|---|
US (1) | US8097592B2 (ja) |
EP (1) | EP2009010A4 (ja) |
JP (1) | JP5210154B2 (ja) |
KR (2) | KR101243039B1 (ja) |
CN (1) | CN101443328B (ja) |
AU (1) | AU2007232763B2 (ja) |
BR (1) | BRPI0710581A2 (ja) |
CA (1) | CA2649022C (ja) |
IL (1) | IL194512A0 (ja) |
MX (1) | MX2008012705A (ja) |
NO (1) | NO20084659L (ja) |
RU (1) | RU2408595C2 (ja) |
TW (1) | TWI370818B (ja) |
WO (1) | WO2007114475A1 (ja) |
ZA (1) | ZA200809201B (ja) |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009096455A1 (ja) | 2008-01-31 | 2009-08-06 | Astellas Pharma Inc. | 脂肪性肝疾患の治療用医薬組成物 |
WO2010022313A3 (en) * | 2008-08-22 | 2010-06-17 | Theracos, Inc. | Processes for the preparation of sglt2 inhibitors |
WO2011049191A1 (ja) * | 2009-10-23 | 2011-04-28 | アステラス製薬株式会社 | 経口投与用医薬組成物 |
US8129434B2 (en) | 2007-12-13 | 2012-03-06 | Theracos, Inc. | Benzylphenyl cyclohexane derivatives and methods of use |
WO2012041898A1 (en) | 2010-09-29 | 2012-04-05 | Celon Pharma Sp. Z O.O. | Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes |
WO2012062698A1 (en) | 2010-11-08 | 2012-05-18 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US8198464B2 (en) | 2006-12-21 | 2012-06-12 | Astellas Pharma Inc. | Method for producing C-glycoside derivative and intermediate for synthesis thereof |
WO2012107476A1 (en) | 2011-02-09 | 2012-08-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
WO2012144592A1 (ja) * | 2011-04-22 | 2012-10-26 | アステラス製薬株式会社 | 固形医薬組成物 |
WO2012163990A1 (en) | 2011-06-03 | 2012-12-06 | Boehringer Ingelheim International Gmbh | Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents |
JP2014040451A (ja) * | 2009-10-20 | 2014-03-06 | Novartis Ag | グリコシド誘導体およびその使用 |
JP2014513693A (ja) * | 2011-05-09 | 2014-06-05 | ヤンセン ファーマシューティカ エヌ.ベー. | (2s,3r,4r,5s,6r)−2−(3−((5−(4−フルオロフェニル)チオフェン−2−イル)メチル)−4−メチルフェニル)−6−(ヒドロキシメチル)テトラヒドロ−2h−ピラン−3,4,5−トリオールのl−プロリン及びクエン酸との共結晶 |
WO2014101865A1 (zh) * | 2012-12-31 | 2014-07-03 | 上海璎黎科技有限公司 | 葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用 |
WO2014161836A1 (en) | 2013-04-04 | 2014-10-09 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in equine animals |
JP2014532639A (ja) * | 2011-10-31 | 2014-12-08 | サイノファーム タイワン,リミティド | Sglt2阻害剤の結晶および非結晶形態 |
US8987323B2 (en) | 2010-06-12 | 2015-03-24 | Theracos, Inc. | Crystalline form of benzylbenzene SGLT2 inhibitor |
JP2015522644A (ja) * | 2012-07-26 | 2015-08-06 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーBoehringer Ingelheim Vetmedica GmbH | 1−シアノ−2−(4−シクロプロピル−ベンジル)−4−(β−D−グルコピラノース−1−イル)−ベンゼンの結晶性錯体、その調製方法及び薬物を調製するためのその使用 |
US9193751B2 (en) | 2012-04-10 | 2015-11-24 | Theracos, Inc. | Process for the preparation of benzylbenzene SGLT2 inhibitors |
US9464043B2 (en) | 2013-10-12 | 2016-10-11 | Theracos Sub, Llc | Preparation of hydroxy-benzylbenzene derivatives |
WO2017046730A1 (en) | 2015-09-15 | 2017-03-23 | Laurus Labs Private Limited | Co-crystals of sglt2 inhibitors, process for their preparation and pharmaceutical compositions thereof |
EP3485890A1 (en) | 2014-01-23 | 2019-05-22 | Boehringer Ingelheim Vetmedica GmbH | Treatment of metabolic disorders in canine animals |
EP3721882A1 (en) | 2014-04-01 | 2020-10-14 | Boehringer Ingelheim Vetmedica GmbH | Treatment of metabolic disorders in equine animals |
JP2021505674A (ja) * | 2017-12-11 | 2021-02-18 | アーテロ バイオサイエンシズ,インコーポレイテッド | カンナビジオールの新しい固体形態およびその使用 |
WO2021105152A1 (en) | 2019-11-28 | 2021-06-03 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors in the drying-off of non-human mammals |
EP3862003A1 (en) | 2013-12-17 | 2021-08-11 | Boehringer Ingelheim Vetmedica GmbH | An sglt-2 inhibitor for use in the treatment of a metabolic disorder in feline animals |
WO2021165177A1 (en) | 2020-02-17 | 2021-08-26 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines |
WO2021214023A1 (en) | 2020-04-22 | 2021-10-28 | Bayer Aktiengesellschaft | Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases |
WO2023006747A1 (en) | 2021-07-28 | 2023-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals |
WO2023006718A1 (en) | 2021-07-28 | 2023-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines |
WO2023006745A1 (en) | 2021-07-28 | 2023-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals |
WO2023129595A1 (en) | 2021-12-30 | 2023-07-06 | Newamsterdam Pharma B.V. | Obicetrapib and sglt2 inhibitor combination |
WO2023227492A1 (en) | 2022-05-25 | 2023-11-30 | Boehringer Ingelheim Vetmedica Gmbh | Aqueous pharmaceutical compositions comprising sglt-2 inhibitors |
EP4403230A2 (en) | 2014-09-25 | 2024-07-24 | Boehringer Ingelheim Vetmedica GmbH | Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals |
WO2024184293A1 (en) | 2023-03-06 | 2024-09-12 | Boehringer Ingelheim Vetmedica Gmbh | Systems for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI309980B (en) * | 2003-03-14 | 2009-05-21 | Yamanouchi Pharma Co Ltd | C-glycoside derivatives or salts thereof |
TW200726755A (en) * | 2005-07-07 | 2007-07-16 | Astellas Pharma Inc | A crystalline choline salt of an azulene derivative |
TWI370818B (en) | 2006-04-05 | 2012-08-21 | Astellas Pharma Inc | Cocrystal of c-glycoside derivative and l-proline |
RS52236B (en) * | 2008-08-28 | 2012-10-31 | Pfizer Inc. | DIOKASA-BICYCLE DERIVATIVES (3.2.1) OCTOBER-2,3,4-TRIOLA |
US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
ES2527179T3 (es) | 2009-11-02 | 2015-01-21 | Pfizer Inc. | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol |
WO2011060256A2 (en) | 2009-11-13 | 2011-05-19 | Bristol-Myers Squibb Company | Bilayer tablet formulations |
RU2564901C2 (ru) | 2009-11-13 | 2015-10-10 | Бристол-Майерс Сквибб Кампани | Композиции метформина с уменьшенной массой |
PL2498759T3 (pl) | 2009-11-13 | 2019-03-29 | Astrazeneca Ab | Formulacje tabletek o natychmiastowym uwalnianiu |
WO2011143296A1 (en) | 2010-05-11 | 2011-11-17 | Janssen Pharmaceutica Nv | Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt |
EP2611442B1 (en) | 2010-09-03 | 2018-07-04 | Bristol-Myers Squibb Company | Drug formulations using water soluble antioxidants |
JP2014504639A (ja) | 2011-02-01 | 2014-02-24 | ブリストル−マイヤーズ スクイブ カンパニー | アミン化合物を含む医薬製剤 |
WO2012116349A2 (en) * | 2011-02-26 | 2012-08-30 | Amplio Pharma, Llc | Novel cocrystals of ezetimibe |
PL2697218T3 (pl) | 2011-04-13 | 2016-11-30 | Sposób wytwarzania związków użytecznych, jako inhibitory SGLT2 | |
ITMI20120586A1 (it) | 2012-04-11 | 2013-10-12 | Milano Politecnico | Co-cristalli di 3-iodiopropinil butilcarbammato |
RU2497804C1 (ru) * | 2012-05-02 | 2013-11-10 | Федеральное государственное бюджетное учреждение науки институт химии растворов им. Г.А. Крестова Российской академии наук | Сокристаллическая форма 2-гидроксибензамида с 4-аминобензойной кислотой |
EP2722327A1 (en) * | 2012-10-22 | 2014-04-23 | Quantum Genomics | Crystalline phase of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) with L-lysine |
CN104098572A (zh) * | 2013-04-08 | 2014-10-15 | 博瑞生物医药技术(苏州)有限公司 | 替卡格雷共晶型 |
CN103626710A (zh) * | 2013-12-20 | 2014-03-12 | 苏州晶云药物科技有限公司 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸的共晶及其制备方法 |
WO2015095703A1 (en) * | 2013-12-20 | 2015-06-25 | Crystal Pharmatech, Inc. | Novel salts and co-crystals of lesinurad |
KR101613488B1 (ko) | 2014-06-18 | 2016-04-20 | (주) 디엔디이 | Mice 행사용 초대장 회답 통합관리시스템 |
CN104017031A (zh) * | 2014-06-21 | 2014-09-03 | 李友香 | 降血糖药物和组合物 |
CN104031098A (zh) * | 2014-06-21 | 2014-09-10 | 李友香 | 降糖药物 |
WO2017032799A1 (en) | 2015-08-27 | 2017-03-02 | Boehringer Ingelheim Vetmedica Gmbh | Liquid pharmaceutical compositions comprising sglt-2 inhibitors |
CN106924206A (zh) * | 2015-12-31 | 2017-07-07 | 深圳翰宇药业股份有限公司 | 一种依格列净口服固体制剂及其制备方法 |
US20190343853A1 (en) * | 2018-04-25 | 2019-11-14 | Theracos Sub, Llc | Methods of treating hypertension |
KR102097250B1 (ko) | 2019-11-09 | 2020-04-03 | 유니셀랩 주식회사 | 신규한 이프라글리플로진의 결정형, 이의 제조방법 또는 용도 |
KR102660615B1 (ko) | 2020-10-28 | 2024-04-26 | 동방에프티엘(주) | 이프라글리플로진의 신규 공결정 및 이의 제조 방법 |
CN113234028B (zh) * | 2021-04-29 | 2022-08-26 | 上海大学 | 一种5-氟尿嘧啶与肌氨酸的共晶体及其制备方法与用途 |
KR20240044194A (ko) * | 2022-09-28 | 2024-04-04 | 주식회사 대웅제약 | 이나보글리플로진의 신규한 공결정 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004080990A1 (ja) | 2003-03-14 | 2004-09-23 | Astellas Pharma Inc. | C-グリコシド誘導体又はその塩 |
WO2005023198A2 (en) * | 2003-09-04 | 2005-03-17 | Cephalon, Inc. | Modafinil compositions |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0600232A2 (en) * | 2001-04-11 | 2006-08-28 | Bristol Myers Squibb Co | Amino acid complexes of c-aryl glucosides for treatment of diabetes and method |
CN103819465A (zh) | 2003-08-01 | 2014-05-28 | 田边三菱制药株式会社 | 新颖化合物 |
TWI370818B (en) | 2006-04-05 | 2012-08-21 | Astellas Pharma Inc | Cocrystal of c-glycoside derivative and l-proline |
US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
US8198464B2 (en) | 2006-12-21 | 2012-06-12 | Astellas Pharma Inc. | Method for producing C-glycoside derivative and intermediate for synthesis thereof |
-
2007
- 2007-04-03 TW TW096111913A patent/TWI370818B/zh not_active IP Right Cessation
- 2007-04-04 RU RU2008143362/04A patent/RU2408595C2/ru not_active IP Right Cessation
- 2007-04-04 AU AU2007232763A patent/AU2007232763B2/en not_active Ceased
- 2007-04-04 CA CA2649022A patent/CA2649022C/en not_active Expired - Fee Related
- 2007-04-04 WO PCT/JP2007/057597 patent/WO2007114475A1/ja active Application Filing
- 2007-04-04 US US12/296,056 patent/US8097592B2/en not_active Expired - Fee Related
- 2007-04-04 JP JP2008508716A patent/JP5210154B2/ja active Active
- 2007-04-04 CN CN2007800169018A patent/CN101443328B/zh active Active
- 2007-04-04 EP EP07741033A patent/EP2009010A4/en not_active Withdrawn
- 2007-04-04 KR KR1020087027002A patent/KR101243039B1/ko active IP Right Review Request
- 2007-04-04 KR KR1020127002361A patent/KR20120025001A/ko not_active Application Discontinuation
- 2007-04-04 MX MX2008012705A patent/MX2008012705A/es active IP Right Grant
- 2007-04-04 BR BRPI0710581-9A patent/BRPI0710581A2/pt not_active IP Right Cessation
-
2008
- 2008-10-02 IL IL194512A patent/IL194512A0/en not_active IP Right Cessation
- 2008-10-27 ZA ZA2008/09201A patent/ZA200809201B/en unknown
- 2008-11-04 NO NO20084659A patent/NO20084659L/no not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004080990A1 (ja) | 2003-03-14 | 2004-09-23 | Astellas Pharma Inc. | C-グリコシド誘導体又はその塩 |
WO2005023198A2 (en) * | 2003-09-04 | 2005-03-17 | Cephalon, Inc. | Modafinil compositions |
Non-Patent Citations (4)
Title |
---|
MANIATIS ET AL., MOLECULAR CLONING |
ROGOWSKA P. ET AL.: "Evidence for strong heterodimeric interactions of phenylboronic acids with amino acids", TETRAHEDRON LETTERS, vol. 47, no. 9, February 2006 (2006-02-01), pages 1389 - 1393, XP005267547 * |
See also references of EP2009010A4 |
WELLS R. G. ET AL., AM. J. PHYSIOL., vol. 263, no. 3, 1992, pages F459 |
Cited By (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8198464B2 (en) | 2006-12-21 | 2012-06-12 | Astellas Pharma Inc. | Method for producing C-glycoside derivative and intermediate for synthesis thereof |
US8129434B2 (en) | 2007-12-13 | 2012-03-06 | Theracos, Inc. | Benzylphenyl cyclohexane derivatives and methods of use |
WO2009096455A1 (ja) | 2008-01-31 | 2009-08-06 | Astellas Pharma Inc. | 脂肪性肝疾患の治療用医薬組成物 |
US20110003757A1 (en) * | 2008-01-31 | 2011-01-06 | Astellas Pharma Inc. | Pharmaceutical compositions for treating fatty liver disease |
KR101516677B1 (ko) * | 2008-01-31 | 2015-05-04 | 고토부키 세이야쿠 가부시키가이샤 | 지방성 간 질환의 치료용 의약 조성물 |
JP5302900B2 (ja) * | 2008-01-31 | 2013-10-02 | アステラス製薬株式会社 | 脂肪性肝疾患の治療用医薬組成物 |
CN101969944B (zh) * | 2008-01-31 | 2013-04-10 | 安斯泰来制药有限公司 | 脂肪性肝病的治疗用医药组合物 |
US9006403B2 (en) | 2008-08-22 | 2015-04-14 | Theracos, Inc. | Processes for the preparation of SGLT2 inhibitors |
RU2641905C2 (ru) * | 2008-08-22 | 2018-01-23 | Теракос Саб,ЛЛК. | Кристаллические формы комплексов, полезные в качестве ингибиторов sglt2, и способы их получения |
US8283454B2 (en) | 2008-08-22 | 2012-10-09 | Theracos, Inc. | Processes for the preparation of SGLT2 inhibitors |
WO2010022313A3 (en) * | 2008-08-22 | 2010-06-17 | Theracos, Inc. | Processes for the preparation of sglt2 inhibitors |
RU2530494C2 (ru) * | 2008-08-22 | 2014-10-10 | Теракос, Инк. | Способ получения ингибиторов sglt2 |
JP2014040451A (ja) * | 2009-10-20 | 2014-03-06 | Novartis Ag | グリコシド誘導体およびその使用 |
KR101465308B1 (ko) * | 2009-10-20 | 2014-11-28 | 노파르티스 아게 | 글리코시드 유도체 및 그의 용도 |
JP4759102B2 (ja) * | 2009-10-23 | 2011-08-31 | アステラス製薬株式会社 | 経口投与用医薬組成物 |
WO2011049191A1 (ja) * | 2009-10-23 | 2011-04-28 | アステラス製薬株式会社 | 経口投与用医薬組成物 |
US8987323B2 (en) | 2010-06-12 | 2015-03-24 | Theracos, Inc. | Crystalline form of benzylbenzene SGLT2 inhibitor |
US10533032B2 (en) | 2010-06-12 | 2020-01-14 | Theracos Sub, Llc | Crystalline form of benzylbenzene SGLT2 inhibitor |
US9834573B2 (en) | 2010-06-12 | 2017-12-05 | Theracos Sub, Llc | Crystalline form of benzylbenzene SGLT2 inhibitor |
US10981942B2 (en) | 2010-06-12 | 2021-04-20 | Theracos Sub, Llc | Crystalline form of benzylbenzene SGLT2 inhibitor |
WO2012041898A1 (en) | 2010-09-29 | 2012-04-05 | Celon Pharma Sp. Z O.O. | Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes |
EP3539540A1 (en) | 2010-11-08 | 2019-09-18 | Boehringer Ingelheim International GmbH | Pharmaceutical composition, methods for treating and uses thereof |
WO2012062698A1 (en) | 2010-11-08 | 2012-05-18 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
WO2012107476A1 (en) | 2011-02-09 | 2012-08-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
WO2012144592A1 (ja) * | 2011-04-22 | 2012-10-26 | アステラス製薬株式会社 | 固形医薬組成物 |
JPWO2012144592A1 (ja) * | 2011-04-22 | 2014-07-28 | アステラス製薬株式会社 | 固形医薬組成物 |
JP6063379B2 (ja) * | 2011-04-22 | 2017-01-18 | アステラス製薬株式会社 | 固形医薬組成物 |
US9035044B2 (en) | 2011-05-09 | 2015-05-19 | Janssen Pharmaceutica Nv | L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
JP2014513693A (ja) * | 2011-05-09 | 2014-06-05 | ヤンセン ファーマシューティカ エヌ.ベー. | (2s,3r,4r,5s,6r)−2−(3−((5−(4−フルオロフェニル)チオフェン−2−イル)メチル)−4−メチルフェニル)−6−(ヒドロキシメチル)テトラヒドロ−2h−ピラン−3,4,5−トリオールのl−プロリン及びクエン酸との共結晶 |
WO2012163990A1 (en) | 2011-06-03 | 2012-12-06 | Boehringer Ingelheim International Gmbh | Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents |
JP2014532639A (ja) * | 2011-10-31 | 2014-12-08 | サイノファーム タイワン,リミティド | Sglt2阻害剤の結晶および非結晶形態 |
US9725478B2 (en) | 2012-04-10 | 2017-08-08 | Theracos Sub, Llc | Process for the preparation of benzylbenzene SGLT2 inhibitors |
US9193751B2 (en) | 2012-04-10 | 2015-11-24 | Theracos, Inc. | Process for the preparation of benzylbenzene SGLT2 inhibitors |
JP2015522644A (ja) * | 2012-07-26 | 2015-08-06 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーBoehringer Ingelheim Vetmedica GmbH | 1−シアノ−2−(4−シクロプロピル−ベンジル)−4−(β−D−グルコピラノース−1−イル)−ベンゼンの結晶性錯体、その調製方法及び薬物を調製するためのその使用 |
JP2016504340A (ja) * | 2012-12-31 | 2016-02-12 | チャイナ ゲートウェイ ファーマシューティカル ディベロプメント カンパニー リミテッド | ブドウ糖誘導体とプロリンの複合物、結晶体、その製造方法及び使用 |
WO2014101865A1 (zh) * | 2012-12-31 | 2014-07-03 | 上海璎黎科技有限公司 | 葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用 |
US9738603B2 (en) | 2012-12-31 | 2017-08-22 | Shanghai Yingli Pharmaceutical Co., Ltd. | Complex of glucose derivative and proline, crystal, preparation method and use |
EP4245765A2 (en) | 2013-04-04 | 2023-09-20 | Boehringer Ingelheim Vetmedica GmbH | Treatment of metabolic disorders in equine animals |
WO2014161836A1 (en) | 2013-04-04 | 2014-10-09 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in equine animals |
US10093616B2 (en) | 2013-10-12 | 2018-10-09 | Theracos Sub, Llc | Preparation of hydroxy-benzylbenzene derivatives |
US9464043B2 (en) | 2013-10-12 | 2016-10-11 | Theracos Sub, Llc | Preparation of hydroxy-benzylbenzene derivatives |
EP4285995A2 (en) | 2013-12-17 | 2023-12-06 | Boehringer Ingelheim Vetmedica GmbH | An sglt-2 inhibitor for use in the treatment of a metabolic disorder in feline animals |
EP3862003A1 (en) | 2013-12-17 | 2021-08-11 | Boehringer Ingelheim Vetmedica GmbH | An sglt-2 inhibitor for use in the treatment of a metabolic disorder in feline animals |
EP4234012A2 (en) | 2014-01-23 | 2023-08-30 | Boehringer Ingelheim Vetmedica GmbH | Sglt2 inhibitors for treatment of metabolic disorders in canine animals |
EP3485890A1 (en) | 2014-01-23 | 2019-05-22 | Boehringer Ingelheim Vetmedica GmbH | Treatment of metabolic disorders in canine animals |
EP3721882A1 (en) | 2014-04-01 | 2020-10-14 | Boehringer Ingelheim Vetmedica GmbH | Treatment of metabolic disorders in equine animals |
EP4403230A2 (en) | 2014-09-25 | 2024-07-24 | Boehringer Ingelheim Vetmedica GmbH | Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals |
US10428053B2 (en) | 2015-09-15 | 2019-10-01 | Laurus Labs Limited | Co-crystals of SGLT2 inhibitors, process for their preparation and pharmaceutical compositions thereof |
US10836753B2 (en) | 2015-09-15 | 2020-11-17 | Laurus Labs Limited | Co-crystals of SGLT2 inhibitors, process for their preparation and pharmaceutical compositions thereof |
US10738038B2 (en) | 2015-09-15 | 2020-08-11 | Laurus Labs Limited | Co-crystals of SGLT2 inhibitors, process for their preparation and pharmaceutical compositions thereof |
US11040961B2 (en) | 2015-09-15 | 2021-06-22 | Laurus Labs Limited | Co-crystals of SGLT2 inhibitors, process for their preparation and pharmaceutical compositions thereof |
WO2017046730A1 (en) | 2015-09-15 | 2017-03-23 | Laurus Labs Private Limited | Co-crystals of sglt2 inhibitors, process for their preparation and pharmaceutical compositions thereof |
JP2021505674A (ja) * | 2017-12-11 | 2021-02-18 | アーテロ バイオサイエンシズ,インコーポレイテッド | カンナビジオールの新しい固体形態およびその使用 |
JP7429013B2 (ja) | 2017-12-11 | 2024-02-07 | アーテロ バイオサイエンシズ,インコーポレイテッド | カンナビジオールの新しい固体形態およびその使用 |
WO2021105152A1 (en) | 2019-11-28 | 2021-06-03 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors in the drying-off of non-human mammals |
WO2021165177A1 (en) | 2020-02-17 | 2021-08-26 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines |
WO2021214023A1 (en) | 2020-04-22 | 2021-10-28 | Bayer Aktiengesellschaft | Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases |
WO2023006745A1 (en) | 2021-07-28 | 2023-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals |
WO2023006718A1 (en) | 2021-07-28 | 2023-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines |
WO2023006747A1 (en) | 2021-07-28 | 2023-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals |
WO2023129595A1 (en) | 2021-12-30 | 2023-07-06 | Newamsterdam Pharma B.V. | Obicetrapib and sglt2 inhibitor combination |
WO2023227492A1 (en) | 2022-05-25 | 2023-11-30 | Boehringer Ingelheim Vetmedica Gmbh | Aqueous pharmaceutical compositions comprising sglt-2 inhibitors |
WO2024184293A1 (en) | 2023-03-06 | 2024-09-12 | Boehringer Ingelheim Vetmedica Gmbh | Systems for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s) |
Also Published As
Publication number | Publication date |
---|---|
BRPI0710581A2 (pt) | 2011-08-16 |
RU2408595C2 (ru) | 2011-01-10 |
ZA200809201B (en) | 2009-12-30 |
TWI370818B (en) | 2012-08-21 |
KR20090015912A (ko) | 2009-02-12 |
US20090143316A1 (en) | 2009-06-04 |
CN101443328B (zh) | 2012-07-25 |
JP5210154B2 (ja) | 2013-06-12 |
RU2008143362A (ru) | 2010-05-10 |
NO20084659L (no) | 2009-01-02 |
MX2008012705A (es) | 2008-10-15 |
US8097592B2 (en) | 2012-01-17 |
EP2009010A4 (en) | 2012-06-13 |
EP2009010A1 (en) | 2008-12-31 |
CA2649022A1 (en) | 2007-10-11 |
AU2007232763A1 (en) | 2007-10-11 |
TW200811152A (en) | 2008-03-01 |
IL194512A0 (en) | 2009-08-03 |
KR101243039B1 (ko) | 2013-03-20 |
CN101443328A (zh) | 2009-05-27 |
JPWO2007114475A1 (ja) | 2009-08-20 |
AU2007232763B2 (en) | 2011-07-28 |
KR20120025001A (ko) | 2012-03-14 |
CA2649022C (en) | 2012-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007114475A1 (ja) | C-グリコシド誘導体とl-プロリンとの共結晶 | |
TWI500622B (zh) | 雜環衍生物 | |
TWI309980B (en) | C-glycoside derivatives or salts thereof | |
RU2430099C2 (ru) | Тозилатная соль терапевтического соединения и ее фармацевтические композиции | |
CN102695546B (zh) | 作为谷氨酰胺酰环化酶抑制剂的杂环衍生物 | |
JPWO2007007628A1 (ja) | アズレン系化合物のコリン塩結晶 | |
WO2001047883A1 (en) | Fused-ring compounds and use thereof as drugs | |
JP2005531516A (ja) | 選択的ep4受容体アゴニストによる治療方法 | |
TWI382018B (zh) | 新穎組胺酸衍生物 | |
EA007328B1 (ru) | Тиазолидинкарбоксамидные производные как модуляторы рецептора простагландина f | |
WO2012103113A1 (en) | Pyrazine and imidazolidine derivatives and their uses to treat hepatitis c | |
WO1996038415A1 (fr) | Nouveaux derives de l'acide 2-amino-3-phenylpropionique | |
JP4937435B2 (ja) | 新規化合物およびその医薬用途 | |
JP2013515766A (ja) | イマチニブジクロロ酢酸塩及びそれを含む抗癌剤組成物 | |
JP3539926B2 (ja) | 抗ウイルス性ピリミジンジオン誘導体及びそれらの製造方法 | |
JP5859115B2 (ja) | 1,4−ジヒドロピリジン−3,5−ジカルボキシラート誘導体、その調製方法及びその使用 | |
WO1996015117A1 (fr) | Compose optiquement actif | |
WO1996005820A1 (fr) | Medicament contre l'hyperlipemie | |
TW201102380A (en) | Novel heterocyclic compounds | |
TW201625588A (zh) | 環狀胺衍生物 | |
KR102660615B1 (ko) | 이프라글리플로진의 신규 공결정 및 이의 제조 방법 | |
JP5597400B2 (ja) | ヒスチジン誘導体を含有する医薬 | |
JP2020143085A (ja) | サクビトリルカルシウム塩 | |
HUT73432A (en) | Bicyclic substituted oxazol- and thiazol-ethers | |
TW202342060A (zh) | Lonp1抑制劑化合物、用途及方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07741033 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/012705 Country of ref document: MX Ref document number: 194512 Country of ref document: IL Ref document number: 2649022 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12296056 Country of ref document: US Ref document number: 2008508716 Country of ref document: JP Ref document number: 12008502226 Country of ref document: PH |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007232763 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4367/KOLNP/2008 Country of ref document: IN Ref document number: 2007741033 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087027002 Country of ref document: KR Ref document number: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008143362 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200780016901.8 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2007232763 Country of ref document: AU Date of ref document: 20070404 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0710581 Country of ref document: BR Kind code of ref document: A2 Effective date: 20081006 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020127002361 Country of ref document: KR |